A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations
1. Crown Bioscience, Inc., 3375 Scott Blvd, Santa Clara, CA 95054, USA;2. State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China